Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
Background: Gout is a common disease and is usually treated with uric acid-lowering drugs (the most commonly used of which are febuxostat and allopurinol). However, the cardiovascular safety of febuxostat and allopurinol is still controversial. The purpose of our study is to evaluate the cardiovascu...
Main Authors: | Xudong Guan, Shengzhao Zhang, Jiayan Liu, Fengbo Wu, Lingyan Zhou, Ying Liu, Na Su |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-09-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.998441/full |
Similar Items
-
Hepatic Safety of Febuxostat and Allopurinol for Gout Patients: A Systematic Review of Randomized Controlled Trial
by: Dewi C, et al.
Published: (2023-09-01) -
Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
by: Shengzhao Zhang, et al.
Published: (2021-06-01) -
Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
by: Ajinkya Pawar, et al.
Published: (2021-04-01) -
Sex difference in heart failure risk associated with febuxostat and allopurinol in gout patients
by: Ching-Lan Cheng, et al.
Published: (2022-08-01) -
CARDIOVASCULAR DISEASES AT GOUT
by: O.V. Berzin, et al.
Published: (2018-09-01)